NCT02989194View on ClinicalTrials.gov

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

October 27, 2017

Study Completion Date

October 27, 2017

Conditions
Influenza
Interventions
DRUG

VIS410 low dose

Single intravenous fixed low dose of VIS410

DRUG

VIS410 high dose

Single intravenous fixed high dose of VIS410

DRUG

Placebo

Single intravenous infusion of placebo

Trial Locations (54)

1035

Witbank

1055

Middelburg

1202

Sofia

1407

Sofia

1500

Benoni

1619

Kempton Park

1692

Centurion

2013

Soweto

2113

Johannesburg

3600

Lom

4092

Durban

4230

Asenovgrad

4600

Velingrad

6850

Worcester

7002

Rousse

7570

Cape Town

9460

Welkom

10617

Tallinn

11615

Tallinn

13415

Tallinn

18000

Niš

21000

Novi Sad

21001

Vinnytsia

21029

Vinnytsia

28150

Shelby

32811

Orlando

33033

Homestead

33134

Coral Gables

33165

Miami

33185

Miami

34000

Kragujevac

35801

Huntsville

40021

Sumy

61064

Kharkiv

61106

Kharkiv

65023

Odesa

70115

New Orleans

70535

Eunice

72713

Paide

77058

Houston

78504

McAllen

LV-5417

Daugavpils

LV-3414

Liepāja

LV-4600

Rēzekne

LV-1010

Riga

LV-4201

Valmiera

LV-3601

Ventspils

0121

Pretoria

0183

Pretoria West

0152

Soshanguve

0380

Thabazimbi

03049

Kiev

03110

Kiev

04050

Kiev

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Visterra, Inc.

INDUSTRY

NCT02989194 - Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A | Biotech Hunter | Biotech Hunter